Neuro-oncology
TME Pharma AG focuses on glioblastoma, with clinical interest centered on newly diagnosed disease and unmethylated MGMT promoter status.
- Glioblastoma
- Neuro-oncology
- Newly diagnosed brain tumours
The company’s research activity in this area is directed toward treatment settings that address aggressive central nervous system malignancy.
Radiation-based cancer therapy
The sponsor’s trial portfolio includes radiation therapy in combination with investigational treatment for glioblastoma, reflecting a therapeutic interest in multimodal oncologic care.
- Radiation therapy
- Combination cancer treatment
- Local tumour control
This area of research links radiotherapy with systemic approaches used in difficult-to-treat brain cancer.
Immuno-oncology
TME Pharma AG is also involved in immuno-oncology, with trial activity examining treatment combinations that include pembrolizumab in glioblastoma.
- Immune checkpoint inhibition
- Pembrolizumab
- Anti-tumour immune response
Its research interest extends to integrating immune-targeted therapy within brain tumour treatment strategies.
Anti-angiogenic therapy
The sponsor’s clinical research includes bevacizumab-containing combinations, indicating interest in anti-angiogenic therapy for glioblastoma.
- Bevacizumab
- Angiogenesis inhibition
- Tumour vascular targeting
This therapeutic domain is relevant to managing the vascular biology associated with aggressive brain tumours.
Targeted nucleic acid therapeutics
TME Pharma AG’s trial activity includes olaptesed pegol in combination regimens, highlighting interest in targeted nucleic acid therapeutics for oncology.
- Olaptesed pegol
- NOX-A12
- Investigational oncology therapies
The company’s research landscape is concentrated on therapeutic combinations developed for glioblastoma treatment.
